INSIGHTS ON CLINICAL TRIAL PARTNERING

• How To Boost Disclosure Efficiencies With Outsourcing

  In this webinar, you’ll hear about exciting new advisory and managed disclosure services from TrialScope, including: compliance, policy and process assessments, as well as plain-language summaries, protocol registration, results posting, and redaction services.

• Driving Product Development And Finding The Fast Track In Early-Phase Oncology Programs

  This webinar highlights the many aspects a company must consider in planning and executing a trial, and how a CRO can help throughout the process.

• Closed Loop Technology And Integrated Expertise Mitigates Risk

  Discover how Almac helped one pharmaceutical company streamline processes and remove risk from their multiple clinical trial applications while maintaining data integrity with One Unified Clinical Trial Supply Solution.

• A Better Way To Pay Clinical Research Sites: Automating Site Grant Payments

  How automating site grant payments can optimize payment processes for sites leading to greater site satisfaction and allowing sites to operate at peak performance and reduce errors.

• An Animal Study That You Won’t Forget

  For a long time, scientists have been trying to understand how neurodegenerative diseases, such as Alzheimer’s and dementia, develop. This is difficult to do partly because you can’t easily obtain samples of brain tissue from live humans. Read about why recent study is making history in the field of Alzheimer’s research.

• CRO Selection Taken Seriously

  Industry Standard Research (ISR) asked over 500 clinical-development outsourcers their level of agreement with the statement: My organization’s mix of CROs is not likely to change much in the next two years.

• Boosting Immuno-Oncology’s Effectiveness Against Cancer

  The current limitations on the use of immunotherapy drugs could be swept away thanks to the development of immune checkpoint inhibitors. They block disruptive proteins that limit the body’s natural immune response and stop T-Cells from destroying cancer cells. Some of the biggest factors stopping the more widespread use of these drugs are the limitations of current standards in effectively measuring how well they work. Read how improvements in the methods used for immuno-oncology drug trials could benefit both researchers and patients.

• Cellular Therapy In Neurological Diseases

  A look at the latest advances in this area as well as challenges that sponsors face when running cell therapy-based trials.

• Compensating Participants In Clinical Research: Current Thinking

  New research on how people make decisions about research participation, and new approaches to the question of payments and compensation to participants, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.